Refine
Has Fulltext
- yes (53)
Is part of the Bibliography
- yes (53)
Year of publication
- 2022 (53) (remove)
Document Type
- Journal article (53) (remove)
Keywords
- heart failure (6)
- biomarkers (3)
- metabolomics (3)
- ACTH (2)
- C-X-C motif chemokine receptor 4 (2)
- CXCR4 (2)
- Cushing’s syndrome (2)
- Fabry disease (2)
- GFAP (2)
- SOAT1 (2)
- [68Ga]PentixaFor (2)
- adrenocortical carcinoma (2)
- cardiac (2)
- endoradiotherapy (2)
- hypercortisolism (2)
- melanoma (2)
- miRNA (2)
- myocardial infarction (2)
- neurofilament light chain (2)
- obesity (2)
- radial (2)
- theranostics (2)
- therapy (2)
- troponin (2)
- ACC (1)
- Alzheimer’s dementia (1)
- BET Inhibitor (1)
- BRAF mutation (1)
- BRD4 (1)
- Brain atrophy (1)
- CMR (1)
- COVID‐19 vaccination (1)
- CRH stimulation test (1)
- CardioMEMS™ HF-System (1)
- Chronic heart failure (1)
- Cognitive decline (1)
- Cushing (1)
- Cushing syndrome (1)
- Cushing's (1)
- Cushing's disease (1)
- DIA-MS (1)
- Dokumentationsqualität (1)
- FGF-pathway (1)
- FGFR (1)
- FGFR-inhibitors (1)
- Fabry Disease (FD) (1)
- Fabry genotype (1)
- Fabry phenotype (1)
- Foxp3 (1)
- GLP-1 (1)
- Gb3 and lyso-Gb3 biomarkers (1)
- Glial fibrillary acidic protein (1)
- HUVEC (1)
- HiGHmed (1)
- IDH1/2 (1)
- Intensivtransport (1)
- Interhospitaltransfer (1)
- JQ1 (1)
- KWIC (1)
- LND (1)
- LNE (1)
- Langzeitbeatmung (1)
- MRI (1)
- MTL30 (1)
- MUST-Score (1)
- Memory dysfunction (1)
- NAFLD (1)
- NASH (1)
- NMR (1)
- NfL (1)
- PET (1)
- PPGL (1)
- RYGB (1)
- Raman micro-spectroscopy (1)
- Rotary EXcitation (REX) (1)
- Roux-en-Y gastric bypass (1)
- SARS‐CoV‐2 infection (1)
- STEMI (1)
- T-cells (1)
- T1rho (1)
- T1ρ (1)
- TT\(_{1rho}\) mapping (1)
- T\(_{1P}\) dispersion (1)
- T\(_{1P}\) mapping (1)
- Tregs (regulatory T cells) (1)
- USP28 (1)
- Weaning (1)
- X-chromosomal inactivation (1)
- [11C]-Choline PET/CT (1)
- [11C]-Methionine (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]PentixaTher (1)
- [90Y]PentixaTher (1)
- [99mTc]-Sestamibi scan (1)
- adrenal cancer (1)
- adrenal surgery (1)
- adrenalectomia (1)
- adrenocortical adenocarcinoma (1)
- adrenocortical adenoma (1)
- adrenocortical cancer (1)
- adrenocortical development (1)
- adrenocortical tumor (1)
- adrenocortical tumors (1)
- adverse effects (1)
- age (1)
- antiphospholipid syndrome (1)
- anti‐SARS‐CoV‐2‐spike IgG (1)
- astrocytoma (1)
- at-home sampling (1)
- atherosclerosis (1)
- biomarker (1)
- blood pressure (1)
- buparlisib (1)
- c-MYC (1)
- cardiac MRI (1)
- cardiac implants (1)
- cardiac magnetic resonance imaging (1)
- cardiac thrombi (1)
- cardiac training group (1)
- cardiomyopathy (1)
- cardiovascular diseases (1)
- cardiovascular drugs (1)
- cardiovascular genetics (1)
- cardiovascular risk factors (1)
- checkpoint inhibitors (1)
- cholesterol metabolism (1)
- chronic kidney disease (1)
- clinical routine data (1)
- cognitive impairment (1)
- coherent anti-Stokes Raman scattering (CARS) microscopy (1)
- complication (1)
- confounders (1)
- correction (1)
- cortisol (1)
- cytochrome P450 3A4 (CYP3A4) (1)
- dabrafenib (1)
- desmin (1)
- diagnosis (1)
- diagnosis in Fabry disease (1)
- documentation quality (1)
- drug interaction (1)
- drug intoxication (1)
- drug monitoring (1)
- drug toxicity (1)
- drug–drug interactions (DDIs) (1)
- echocardiography (1)
- ectopic (1)
- efficacy (1)
- endocrine cancer (1)
- endogenous hypercortisolism (1)
- endothelial (1)
- eosinophils (1)
- extended matching questions (1)
- female Fabry patients (1)
- fibrosis (1)
- filamin-C (1)
- focused surgical approach (1)
- functional magnetic resonance imaging (1)
- gastric bypass (1)
- gefitinib (1)
- gene variant (1)
- genotype/phenotype correlation (1)
- glial damage (1)
- glial fibrillary acidic protein (1)
- glioblastoma (1)
- graft versus host disease (1)
- healthcare workers (1)
- heart (1)
- heart failure training group (1)
- high dose dexamethasone suppression test (1)
- hydroxy-dabrafenib (1)
- hypertension (1)
- immune-related adverse events (1)
- immunohistochemistry (1)
- immunotherapy-induced hypophysitis (1)
- infarction size (1)
- inflammation (1)
- intensive care transport (1)
- interhospital transfer (1)
- intragastric balloon (1)
- ipilimumab (1)
- ischemic stroke (1)
- isturisa (1)
- lactic acidosis (1)
- left ventricular ejection fraction (1)
- left ventricular performance (1)
- lipid droplets (1)
- liraglutide (1)
- lncRNA (1)
- long-term ventilation (1)
- lung cancer (1)
- lymph node dissection (1)
- lymphadenectomy (1)
- lysosomal storage disease (1)
- m exercise training (1)
- machine learning (1)
- malnutrition (1)
- mapping (1)
- medical data integration center (1)
- medical informatics initiative (1)
- medical students (1)
- medical therapy (1)
- medullary thyroid cancer (1)
- meta-analysis (1)
- metyrapone (1)
- mice (1)
- mitochondria function and morphology (1)
- mitotane (1)
- multi-tyrosine kinase inhibitor (1)
- multicenter (1)
- multiple choice questions (1)
- multiple myeloma (1)
- multivariate data analysis (1)
- myocardial work (1)
- neuroblastoma – diagnosis (1)
- nivolumab (1)
- nutritional counseling (1)
- nutritional medical needs (1)
- nutritional risk screening (1)
- oncology outpatients (1)
- openEHR (1)
- operation (1)
- oscillating biomagnetic fields (1)
- osilodrostat (1)
- outcome (1)
- oxidative stress (1)
- paired (1)
- parathyroid adenoma (1)
- pediatric (1)
- pediatric adrenocortical cancer (1)
- pediatric adrenocortical carcinoma (1)
- pediatric adrenocortical tumor (1)
- pembrolizumab (1)
- peptide tyrosine tyrosine (PYY) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- personalised medicine (1)
- pharmacokinetics (1)
- pheochromocytoma/paraganglioma (1)
- phosphorylated tau protein (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- pituitary (1)
- plasma (1)
- plasma NMR (1)
- population pharmacokinetics (1)
- posaconazole (1)
- preanalytical conditions (1)
- precision medicine (1)
- primary aldosteronism (1)
- primary hyperparathyroidism (1)
- primary hypophysitis (1)
- prognosis (1)
- prognostic markers (1)
- prostate cancer (1)
- proteomic (1)
- pulmonary artery pressure (1)
- quantitative MRI (1)
- radiotherapy (1)
- randomized controlled trial (1)
- rearranged during transfection (1)
- remote monitoring (1)
- renal function (1)
- restrictive cardiomyopathy (1)
- review (1)
- risk prediction scores (1)
- ruxolitinib (1)
- semantic interoperability (1)
- seroprevalence (1)
- sex differences (1)
- shear stress (1)
- short-chain fatty acids (1)
- signal voids (1)
- sleeve gastrectomy (1)
- small animal (1)
- spin lock (1)
- spin-lock (1)
- super-obesity (1)
- survival (1)
- targeted therapy (1)
- targeted treatment (1)
- trametinib (1)
- treatment (1)
- treatment outcome (1)
- uremic toxins (1)
- variant (1)
- vemurafenib (1)
- volume (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- weaning (1)
Institute
- Medizinische Klinik und Poliklinik I (53) (remove)
Sonstige beteiligte Institutionen
Purpose
Pheochromocytomas and Paragangliomas (PPGL) result in chronic catecholamine excess and serious health complications. A recent study obtained a metabolic signature in plasma from PPGL patients; however, its targeted nature may have generated an incomplete picture and a broader approach could provide additional insights. We aimed to characterize the plasma metabolome of PPGL patients before and after surgery, using an untargeted approach, and to broaden the scope of the investigated metabolic impact of these tumors.
Design
A cohort of 36 PPGL patients was investigated. Blood plasma samples were collected before and after surgical tumor removal, in association with clinical and tumor characteristics.
Methods
Plasma samples were analyzed using untargeted nuclear magnetic resonance (NMR) spectroscopy metabolomics. The data were evaluated using a combination of uni- and multi-variate statistical methods.
Results
Before surgery, patients with a nonadrenergic tumor could be distinguished from those with an adrenergic tumor based on their metabolic profiles. Tyrosine levels were significantly higher in patients with high compared to those with low BMI. Comparing subgroups of pre-operative samples with their post-operative counterparts, we found a metabolic signature that included ketone bodies, glucose, organic acids, methanol, dimethyl sulfone and amino acids. Three signals with unclear identities were found to be affected.
Conclusions
Our study suggests that the pathways of glucose and ketone body homeostasis are affected in PPGL patients. BMI-related metabolite levels were also found to be altered, potentially linking muscle atrophy to PPGL. At baseline, patient metabolomes could be discriminated based on their catecholamine phenotype.
Differences between immunotherapy-induced and primary hypophysitis—a multicenter retrospective study
(2022)
Objective
Immune checkpoint inhibitors can cause various immune-related adverse events including secondary hypophysitis. We compared clinical characteristics of immunotherapy-induced hypophysitis (IIH) and primary hypophysitis (PH)
Design
Retrospective multicenter cohort study including 56 patients with IIH and 60 patients with PH.
Methods
All patients underwent extensive endocrine testing. Data on age, gender, symptoms, endocrine dysfunction, MRI, immunotherapeutic agents and autoimmune diseases were collected.
Results
Median time of follow-up was 18 months in IIH and 69 months in PH. The median time from initiation of immunotherapy to IIH diagnosis was 3 months. IIH affected males more frequently than PH (p < 0.001) and led to more impaired pituitary axes in males (p < 0.001). The distribution of deficient adenohypophysial axes was comparable between both entities, however, central hypocortisolism was more frequent (p < 0.001) and diabetes insipidus considerably less frequent in IIH (p < 0.001). Symptoms were similar except that visual impairment occurred more rarely in IIH (p < 0.001). 20 % of IIH patients reported no symptoms at all. Regarding MRI, pituitary stalk thickening was less frequent in IIH (p = 0.009). Concomitant autoimmune diseases were more prevalent in PH patients before the diagnosis of hypophysitis (p = 0.003) and more frequent in IIH during follow-up (p = 0.002).
Conclusions
Clinically, IIH and PH present with similar symptoms. Diabetes insipidus very rarely occurs in IIH. Central hypocortisolism, in contrast, is a typical feature of IIH. Preexisting autoimmunity seems not to be indicative of developing IIH.
A growing body of literature reports on the upregulation of C-X-C motif chemokine receptor 4 (CXCR4) in a variety of cancer entities, rendering this receptor as suitable target for molecular imaging and endoradiotherapy in a theranostic setting. For instance, the CXCR4-targeting positron emission tomography (PET) agent [\(^{68}\)Ga]PentixaFor has been proven useful for a comprehensive assessment of the current status quo of solid tumors, including adrenocortical carcinoma or small-cell lung cancer. In addition, [\(^{68}\)Ga]PentixaFor has also provided an excellent readout for hematological malignancies, such as multiple myeloma, marginal zone lymphoma, or mantle cell lymphoma. PET-based quantification of the CXCR4 capacities in vivo allows for selecting candidates that would be suitable for treatment using the theranostic equivalent [\(^{177}\)Lu]/[\(^{90}\)Y]PentixaTher. This CXCR4-directed theranostic concept has been used as a conditioning regimen prior to hematopoietic stem cell transplantation and to achieve sufficient anti-lymphoma/-tumor activity in particular for malignant tissues that are highly sensitive to radiation, such as the hematological system. Increasing the safety margin, pretherapeutic dosimetry is routinely performed to determine the optimal activity to enhance therapeutic efficacy and to reduce off-target adverse events. The present review will provide an overview of current applications for CXCR4-directed molecular imaging and will introduce the CXCR4-targeted theranostic concept for advanced hematological malignancies.
Background
CXCR4-directed positron emission tomography/computed tomography (PET/CT) has been used as a diagnostic tool in patients with solid tumors. We aimed to determine a potential correlation between tumor burden and radiotracer accumulation in normal organs.
Methods
Ninety patients with histologically proven solid cancers underwent CXCR4-targeted [\(^{68}\)Ga]Ga-PentixaFor PET/CT. Volumes of interest (VOIs) were placed in normal organs (heart, liver, spleen, bone marrow, and kidneys) and tumor lesions. Mean standardized uptake values (SUV\(_{mean}\)) for normal organs were determined. For CXCR4-positive tumor burden, maximum SUV (SUV\(_{max}\)), tumor volume (TV), and fractional tumor activity (FTA, defined as SUV\(_{mean}\) x TV), were calculated. We used a Spearman's rank correlation coefficient (ρ) to derive correlative indices between normal organ uptake and tumor burden.
Results
Median SUV\(_{mean}\) in unaffected organs was 5.2 for the spleen (range, 2.44 – 10.55), 3.27 for the kidneys (range, 1.52 – 17.4), followed by bone marrow (1.76, range, 0.84 – 3.98), heart (1.66, range, 0.88 – 2.89), and liver (1.28, range, 0.73 – 2.45). No significant correlation between SUV\(_{max}\) in tumor lesions (ρ ≤ 0.189, P ≥ 0.07), TV (ρ ≥ -0.204, P ≥ 0.06) or FTA (ρ ≥ -0.142, P ≥ 0.18) with the investigated organs was found.
Conclusions
In patients with solid tumors imaged with [\(^{68}\)Ga]Ga-PentixaFor PET/CT, no relevant tumor sink effect was noted. This observation may be of relevance for therapies with radioactive and non-radioactive CXCR4-directed drugs, as with increasing tumor burden, the dose to normal organs may remain unchanged.
FGF/FGFR signaling regulates embryogenesis, angiogenesis, tissue homeostasis and wound repair by modulating proliferation, differentiation, survival, migration and metabolism of target cells. Understandably, compelling evidence for deregulated FGF signaling in the development and progression of different types of tumors continue to emerge and FGFR inhibitors arise as potential targeted therapeutic agents, particularly in tumors harboring aberrant FGFR signaling. There is first evidence of a dual role of the FGF/FGFR system in both organogenesis and tumorigenesis, of which this review aims to provide an overview. FGF-1 and FGF-2 are expressed in the adrenal cortex and are the most powerful mitogens for adrenocortical cells. Physiologically, they are involved in development and maintenance of the adrenal gland and bind to a family of four tyrosine kinase receptors, among which FGFR1 and FGFR4 are the most strongly expressed in the adrenal cortex. The repeatedly proven overexpression of these two FGFRs also in adrenocortical cancer is thus likely a sign of their participation in proliferation and vascularization, though the exact downstream mechanisms are not yet elucidated. Thus, FGFRs potentially offer novel therapeutic targets also for adrenocortical carcinoma, a type of cancer resistant to conventional antimitotic agents.
Purpose
A successful focused surgical approach in primary hyperparathyroidism (pHPT) relies on accurate preoperative localization of the parathyroid adenoma (PA). Most often, ultrasound is followed by [\(^{99m}\)Tc]-sestamibi scintigraphy, but the value of this approach is disputed. Here, we evaluated the diagnostic approach in patients with surgically treated pHPT in our center with the aim to further refine preoperative diagnostic procedures.
Methods
A single-center retrospective analysis of patients with pHPT from 01/2005 to 08/2021 was carried out followed by evaluation of the preoperative imaging modalities to localize PA. The localization of the PA had to be confirmed intraoperatively by the fresh frozen section and significant dropping of the intraoperative parathyroid hormone (PTH) levels.
Results
From 658 patients diagnosed with pHPT, 30 patients were excluded from the analysis because of surgery for recurrent or persistent disease. Median age of patients was 58.0 (13–93) years and 71% were female. Neck ultrasound was carried out in 91.7% and localized a PA in 76.6%. In 23.4% (135/576) of the patients, preoperative neck ultrasound did not detect a PA. In this group, [\(^{99m}\)Tc]-sestamibi correctly identified PA in only 25.4% of patients. In contrast, in the same cohort, the use of [\(^{11}\)C]-methionine or [\(^{11}\)C]-choline PET resulted in the correct identification of PA in 79.4% of patients (OR 13.23; 95% CI 5.24–33.56).
Conclusion
[\(^{11}\)C]-Methionine or [\(^{11}\)C]-choline PET/CT are superior second-line imaging methods to select patients for a focused surgical approach when previous ultrasound failed to identify PA.
Background
An intragastric balloon is used to cause weight loss in super-obese patients (BMI > 60 kg/m\(^2\)) prior to bariatric surgery. Whether weight loss from intragastric balloon influences that from bariatric surgery is poorly studied.
Methods
In this retrospective, single-center study, the effects of intragastric balloon in 26 patients (BMI 69.26 ± 6.81) on weight loss after bariatric surgery (primary endpoint), postoperative complications within 30 days, hospital readmission, operation time, and MTL30 (secondary endpoints) were evaluated. Fifty-two matched-pair patients without intragastric balloon prior to bariatric surgery were used as controls.
Results
Intragastric balloon resulted in a weight loss of 17.3 ± 14.1 kg (BMI 5.75 ± 4.66 kg/m\(^2\)) with a nadir after 5 months. Surgical and postoperative outcomes including complications were comparable between both groups. Total weight loss was similar in both groups (29.0% vs. 32.2%, p = 0.362). Direct postoperative weight loss was more pronounced in the control group compared to the gastric balloon group (29.16 ± 7.53% vs 23.78 ± 9.89% after 1 year, p < 0.05 and 32.13 ± 10.5% vs 22.21 ± 10.9% after 2 years, p < 0.05), who experienced an earlier nadir and started to regain weight during the follow-up.
Conclusion
A multi-stage therapeutic approach with gastric balloon prior to bariatric surgery in super-obese patients may be effective to facilitate safe surgery. However, with the gastric balloon, pre-treated patients experienced an attenuated postoperative weight loss with an earlier nadir and earlier body weight regain. This should be considered when choosing the appropriate therapeutic regime and managing patients’ expectations.
Background
Remote monitoring of patients with New York Heart Association (NYHA) functional class III heart failure (HF) using daily transmission of pulmonary artery (PA) pressure values has shown a reduction in HF-related hospitalizations and improved quality of life in patients.
Objectives
PASSPORT-HF is a prospective, randomized, open, multicenter trial evaluating the effects of a hemodynamic-guided, HF nurse-led care approach using the CardioMEMS™ HF-System on clinical end points.
Methods and results
The PASSPORT-HF trial has been commissioned by the German Federal Joint Committee (G-BA) to ascertain the efficacy of PA pressure-guided remote care in the German health-care system. PASSPORT-HF includes adult HF patients in NYHA functional class III, who experienced an HF-related hospitalization within the last 12 months. Patients with reduced ejection fraction must be on stable guideline-directed pharmacotherapy. Patients will be randomized centrally 1:1 to implantation of a CardioMEMS™ sensor or control. All patients will receive post-discharge support facilitated by trained HF nurses providing structured telephone-based care. The trial will enroll 554 patients at about 50 study sites. The primary end point is a composite of the number of unplanned HF-related rehospitalizations or all-cause death after 12 months of follow-up, and all events will be adjudicated centrally. Secondary end points include device/system-related complications, components of the primary end point, days alive and out of hospital, disease-specific and generic health-related quality of life including their sub-scales, and laboratory parameters of organ damage and disease progression.
Conclusions
PASSPORT-HF will define the efficacy of implementing hemodynamic monitoring as a novel disease management tool in routine outpatient care.
Trial registration
ClinicalTrials.gov; NCT04398654, 13-MAY-2020.
Purpose
In selected cases of severe Cushing’s syndrome due to uncontrolled ACTH secretion, bilateral adrenalectomy appears unavoidable. Compared with unilateral adrenalectomy (for adrenal Cushing’s syndrome), bilateral adrenalectomy has a perceived higher perioperative morbidity. The aim of the current study was to compare both interventions in endogenous Cushing’s syndrome regarding postoperative outcomes.
Methods
We report a single-center, retrospective cohort study comparing patients with hypercortisolism undergoing bilateral vs. unilateral adrenalectomy during 2008–2021. Patients with adrenal Cushing’s syndrome due to adenoma were compared with patients with ACTH-dependent Cushing’s syndrome (Cushing’s disease and ectopic ACTH production) focusing on postoperative morbidity and mortality as well as long-term survival.
Results
Of 83 patients with adrenalectomy for hypercortisolism (65.1% female, median age 53 years), the indication for adrenalectomy was due to adrenal Cushing’s syndrome in 60 patients (72.2%; 59 unilateral and one bilateral), and due to hypercortisolism caused by Cushing’s disease (n = 16) or non-pituitary uncontrolled ACTH secretion of unknown origin (n = 7) (27.7% of all adrenalectomies). Compared with unilateral adrenalectomy (n = 59), patients with bilateral adrenalectomy (n = 24) had a higher rate of severe complications (0% vs. 33%; p < 0.001) and delayed recovery (median: 10.2% vs. 79.2%; p < 0.001). Using the MTL30 marker, patients with bilateral adrenalectomy fared worse than patients after unilateral surgery (MTL30 positive: 7.2% vs. 25.0% p < 0.001). Postoperative mortality was increased in patients with bilateral adrenalectomy (0% vs. 8.3%; p = 0.081).
Conclusion
While unilateral adrenalectomy for adrenal Cushing’s syndrome represents a safe and definitive therapeutic option, bilateral adrenalectomy to control ACTH-dependent extra-adrenal Cushing’s syndrome or Cushing’s disease is a more complicated intervention with a mortality of nearly 10%.
Hintergrund und Fragestellung
Die Entwöhnung von Beatmungsgeräten wird nicht immer auf der primär behandelnden Intensivstation abgeschlossen. Die Weiterverlegung in andere Behandlungseinrichtungen stellt einen sensiblen Abschnitt in der Behandlung und Rehabilitation des Weaningpatienten dar. Ziel der vorliegenden Studie war die Untersuchung des Überleitungsmanagements und des Interhospitaltransfers von Weaningpatienten unter besonderer Berücksichtigung der Dokumentationsqualität.
Methodik
Es erfolge eine retrospektive Datenanalyse eines Jahrs (2018) auf 2 Intensivstationen eines Universitätsklinikums. Eingeschlossen wurden alle beatmeten Patienten mit folgenden Tracerdiagnosen: COPD, Asthma, Polytrauma, Pneumonie, Sepsis, ARDS und Reanimation (Beatmung > 24 h).
Ergebnisse
Insgesamt konnten 750 Patienten in die Untersuchung eingeschlossen werden (Alter 64 [52, 8–76; Median, IQR]; 32 % weiblich). Davon waren 48 (6,4 %) Patienten zum Zeitpunkt der Verlegung nicht entwöhnt (v. a. Sepsis und ARDS). Die Routinedokumentation war bei den Abschnitten „Spontaneous Breathing Trial“, „Bewertung der Entwöhungsbereitschaft“ und „vermutete Entwöhnbarkeit“ ausreichend, um die Erfüllung der Parameter der S2k-Leitlinie „Prolongiertes Weaning“ adäquat zu beurteilen. Vorwiegend wurden diese Patienten mit Tracheostoma (76 %) in Rehabilitationskliniken (44 %) mittels spezialisierten Rettungsmitteln des arztbegleiteten Patiententransports verlegt (75 %).
Diskussion
Die Verlegung nicht entwöhnter Patienten nach initialem Intensivaufenthalt ist ein relevantes Thema für den Interhospitaltransfer. Die Routinedokumentation eines strukturierten Weaningprozesses ist in Kernelementen ausreichend, um den Weaningprozess lückenlos zu beschreiben. Dies ist für die Kontinuität in der Weiterbehandlung dieser Patienten von großer Bedeutung.